Acadia Collaborated with Stoke to Develop and Commercialize RNA-Based Therapies for Rare Genetic Neurodevelopmental Diseases
Shots:
- Stoke to receive a $60M upfront, ~$907M in milestones along with royalties while both companies will share 50/50 costs globally & profits for the SYNGAP1 program. Acadia gets exclusive licenses for 2 preclinical programs i.e., Rett syndrome (MECP2) & undisclosed neurodevelopmental target
- The collaboration will combine Stoke’s TANGO research platform with Acadia’s expertise to develop RNA-based therapies for rare CNS disorders
- Stoke will lead the research & pre-clinical development activities for Rett syndrome & the undisclosed neurodevelopmental program. Acadia will lead clinical development & commercialization activities & fund the research & pre-clinical activities for 2 targets
Ref: Acadia | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com